Grant of Options

RNS Number : 7334P

Synairgen plc

21 October 2021

 

Press Release

Synairgen plc

('Synairgen' or the 'Company')

Grant of options

Southampton, UK - 21 October 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta (IFN-beta) for the treatment of severe viral lung infections, announces that on 20 October 2021 the Board of Synairgen granted options ('Options') over 428,502 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share to employees of Synairgen Research Limited, a wholly-owned subsidiary of the Company. The Options represent in aggregate 0.21 per cent. of the Company's issued share capital. 

Following this grant, Synairgen has 8,463,223 options in issue, representing 4.20 per cent. of the Company's issued share capital.

Included in the number of Options granted as above, the following Options were issued to Persons Discharging Managerial Responsibilities ('PDMR'), who have no other holdings of ordinary shares or options in the Company:

PDMR	Options Issued
Brooke Clarke	113,636
Richard Francis	113,636
Gareth Walters	120,779

The Options are issued under the Company's Long Term Incentive Plans and are exercisable up to 19 October 2031, subject to the achievement of appropriate performance criteria.

For further information, please contact:

Synairgen plc  

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Brooke Clarke, Head of Communications  

Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone

[e-mail]

Tel: [phone]

MK Strategies, LLC (US Media Relations)

Mary Conway

[e-mail]

Tel: [phone]

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. Granted Fast Track status from the US Food and Drug Administration (FDA) and deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR), Synairgen's Phase III clinical programme is currently evaluating nebulised SNG001 in patients across 17 countries. In a Phase II trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than two-fold chance of recovery to 'no limitation of activities' versus placebo.¹

Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.

References

1 - https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Brooke Clarke
2.	Reason for notification
a)	Position / status	Head of Communications
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	113,636 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	20 October 2021
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Richard Francis
2.	Reason for notification
a)	Position / status	Head of CMC
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	113,636 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	20 October 2021
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Gareth Walters
2.	Reason for notification
a)	Position / status	Chief Regulatory Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument  Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	120,779 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	20 October 2021
f)	Place of the transaction	Outside a trading venue

 

END

 

 

DSHMMBRTMTTTBFB